{"id":"lv5fu2","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LV5FU2 combines leucovorin (folinic acid), 5-fluorouracil (5-FU), and additional agents to enhance antimetabolite activity. Leucovorin potentiates 5-FU by stabilizing its binding to thymidylate synthase, thereby increasing the inhibition of DNA and RNA synthesis in cancer cells. This combination is designed to improve efficacy in colorectal and other solid tumors.","oneSentence":"LV5FU2 is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:36.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Advanced gastric cancer"}]},"trialDetails":[{"nctId":"NCT03301454","phase":"PHASE2","title":"Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2018-08-20","conditions":"Esophageal Cancer, Squamous Cell","enrollment":15},{"nctId":"NCT03217097","phase":"NA","title":"MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-16","conditions":"Neuroendocrine Tumors","enrollment":116},{"nctId":"NCT07124884","phase":"PHASE2","title":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-08-31","conditions":"Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer","enrollment":300},{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT02885753","phase":"PHASE3","title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-12","conditions":"Colorectal Neoplasms","enrollment":348},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT03584711","phase":"PHASE2","title":"FOLFOX + Panitumumab According to a \"Stop and go\" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-26","conditions":"Metastatic Colorectal Cancer","enrollment":118},{"nctId":"NCT06757244","phase":"PHASE2","title":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2025-02-18","conditions":"Pancreas Neoplasms","enrollment":35},{"nctId":"NCT03255434","phase":"PHASE2","title":"LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2017-11-01","conditions":"Stage III Colon Cancer","enrollment":160},{"nctId":"NCT04257461","phase":"PHASE3","title":"A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma","status":"UNKNOWN","sponsor":"Belgian Group of Digestive Oncology","startDate":"2020-02-20","conditions":"Small Bowel Adenocarcinoma","enrollment":30},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT02494973","phase":"PHASE2, PHASE3","title":"Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-05-26","conditions":"Colorectal Cancer","enrollment":104},{"nctId":"NCT05476796","phase":"PHASE2","title":"Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2023-06-23","conditions":"Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":118},{"nctId":"NCT02384759","phase":"PHASE2","title":"Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-05","conditions":"Colorectal Neoplasms","enrollment":117},{"nctId":"NCT02352337","phase":"PHASE2","title":"First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01-12","conditions":"Metastatic Pancreatic Cancer","enrollment":276},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT02355379","phase":"PHASE3","title":"Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01","conditions":"Colonic Adenocarcinoma","enrollment":774},{"nctId":"NCT03351296","phase":"PHASE2","title":"Two Chemotherapy Regimens Plus or Minus Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-06-26","conditions":"Pancreatic Cancer","enrollment":140},{"nctId":"NCT02090101","phase":"PHASE2","title":"Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2014-10-10","conditions":"Metastatic Colorectal Cancer","enrollment":32},{"nctId":"NCT00467142","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2007-01-23","conditions":"Colorectal Cancer","enrollment":62},{"nctId":"NCT04188145","phase":"PHASE3","title":"A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-01-27","conditions":"Metastatic Colorectal Cancer","enrollment":400},{"nctId":"NCT02942706","phase":"PHASE2, PHASE3","title":"Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-11","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT00112658","phase":"PHASE2, PHASE3","title":"Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2004-11","conditions":"Pancreatic Cancer","enrollment":342},{"nctId":"NCT00066274","phase":"PHASE2","title":"Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2002-07-23","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT01417494","phase":"PHASE2","title":"1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2011-07","conditions":"Colorectal Cancer","enrollment":102},{"nctId":"NCT01248299","phase":"PHASE2","title":"Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2011-01","conditions":"Squamous Cell Carcinoma of Esophagus","enrollment":105},{"nctId":"NCT01900717","phase":"PHASE2","title":"Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2011-07","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":102},{"nctId":"NCT01895257","phase":"PHASE3","title":"Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer","status":"UNKNOWN","sponsor":"Universiteit Antwerpen","startDate":"2013-08","conditions":"Colorectal Cancer","enrollment":162},{"nctId":"NCT01802684","phase":"PHASE2","title":"OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-05","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":49},{"nctId":"NCT01964534","phase":"PHASE2","title":"Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-12-12","conditions":"Metastatic Pancreatic Cancer","enrollment":114},{"nctId":"NCT02978313","phase":"PHASE2, PHASE3","title":"Cetuximab Monotherapy Maintenance Treatment in mCRC","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2016-11","conditions":"Colorectal Cancer","enrollment":500},{"nctId":"NCT00303771","phase":"PHASE3","title":"Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2003-06","conditions":"Colorectal Cancer","enrollment":282},{"nctId":"NCT02502370","phase":"PHASE3","title":"Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"","conditions":"Small Bowel Adenocarcinoma, Adjuvant Chemotherapy for SBA","enrollment":100},{"nctId":"NCT00303758","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":202},{"nctId":"NCT01467921","phase":"PHASE2","title":"Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-12","conditions":"Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT00544349","phase":"PHASE2","title":"Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2006-10","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":45},{"nctId":"NCT00189657","phase":"PHASE3","title":"5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer","status":"UNKNOWN","sponsor":"Association Européenne de Recherche en Oncologie","startDate":"","conditions":"Cancer of the Rectum","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LV5FU2","genericName":"LV5FU2","companyName":"Centre Hospitalier Universitaire de Besancon","companyId":"centre-hospitalier-universitaire-de-besancon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LV5FU2 is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Advanced gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}